BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Coun
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics - read this article along with other careers information, tips and advice on BioSpace
Qu Biologics to Receive $6.7 Million in IRAP Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly. Vancouver, BC, October 27, 2022 Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, announced that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
VANCOUVER, British Columbia, Dec. 18, 2020 Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the potential application of Qu’s lung-directed SSI, QBKPN, to prevent and treat infection with SARS-CoV-2, the virus causing COVID-19. Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qu’s immunotherapy platform engages and trains the innate arm of the